Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Abstract

BACKGROUND In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy. We report the final… (More)
DOI: 10.1016/S1470-2045(09)70025-7

Topics

6 Figures and Tables

Cite this paper

@article{Stupp2009EffectsOR, title={Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.}, author={Roger Stupp and Monika Hegi and Warren P. Mason and Martin J. van den Bent and Martin J B Taphoorn and Robert Charles Janzer and Samuel K. Ludwin and Anouk Allgeier and Barbara Jean Fisher and Karl B{\'e}langer and P Hau and Alba Ariela Brandes and Johanna M. M. Gijtenbeek and Christine Marosi and Charles J. Vecht and Karima Mokhtari and Pieter Wesseling and S. A. Gil - Villa and Elizabeth Eisenhauer and Thierry Gorlia and Michael Weller and Denis A Lacombe and J. Gregory Cairncross and Ren{\'e}-Olivier Mirimanoff}, journal={The Lancet. Oncology}, year={2009}, volume={10 5}, pages={459-66} }